Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
Elias Jabbour, Gerhard Zugmaier, Vaibhav Agrawal, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 586-595
Open Access | Times Cited: 21

Showing 21 citing articles:

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
Sumit Gupta, Rachel E. Rau, John A. Kairalla, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 10
Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries
Piya Rujkijyanont, Hiroto Inaba
Leukemia (2024) Vol. 38, Iss. 8, pp. 1649-1662
Closed Access | Times Cited: 8
How to use monoclonal antibody-based therapy in ALL
Erica Brivio, Sujith Samarasinghe
EJC Paediatric Oncology (2025), pp. 100214-100214
Open Access
Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy
Jayastu Senapati, Hagop M. Kantarjian, Diane Habib, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-12
Closed Access
Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia
Clifford M. Csizmar, Mark R. Litzow, Antoine N. Saliba
Cancers (2025) Vol. 17, Iss. 5, pp. 779-779
Open Access
Curing using the Minimal – Strategies For Treatment Reduction In Childhood Acute Lymphoblastic Leukemia
Bernice Oh, Stephen P. Hunger, Allen Eng Juh Yeoh, et al.
EJC Paediatric Oncology (2025), pp. 100222-100222
Open Access
Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective
Carla Nolasco Monteiro Breviglieri, Roseane Vasconcelos Gouveia, Valéria Cortez Ginani, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, et al.
European Journal Of Haematology (2025)
Open Access
CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
Mengting Qin, Jianhua Ren, Xiaodong Chen, et al.
Theranostics (2025) Vol. 15, Iss. 8, pp. 3589-3609
Open Access
Integrating Blinatumomab in the Frontline Treatment in B-Cell Acute Lymphoblastic Leukemia: A New Era in Therapeutic Management
Martina Canichella, Laura De Fazio, Matteo Molica
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 2055-2055
Open Access
Can autoimmune disease be cured by deep CD19+ cell depletion?
Dan Suan, John Moore, Christopher C. Goodnow
The Journal of Immunology (2025)
Open Access
Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation
Jiayu Huang, Bingyang Shi, Shiyou Yu, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia
Ilaria Iacobucci, Cristina Papayannidis
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 2
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia
Madelyn Burkart, Shira Dinner
Blood Reviews (2024) Vol. 66, pp. 101208-101208
Closed Access | Times Cited: 1
Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens
Nicholas J. Short, Hagop M. Kantarjian, Elias Jabbour
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-13
Closed Access
Reduction of HLA antibodies by bi-specific antibody blinatumomab
Xiaohai Zhang
Human Immunology (2024) Vol. 85, Iss. 6, pp. 111163-111163
Closed Access
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes
Shilpa Paul, Elias Jabbour, Dan Nichols, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-11
Closed Access
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia
Ibrahim Aldoss, Gail J. Roboz, R Bassan, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 12, pp. e959-e970
Closed Access
Building a better blinatumomab
Mark R. Litzow
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 512-514
Closed Access
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
Ugo Testa, Elvira Pelosi, Germana Castelli, et al.
Mediterranean Journal of Hematology and Infectious Diseases (2024) Vol. 16, Iss. 1, pp. e2024070-e2024070
Open Access
Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia
Josep‐María Ribera, Anna Torrent
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-11
Closed Access
Page 1

Scroll to top